Answers are grounded in this paper and cite their sources.
In addition to the pathologic parameters and biomarkers already routinely assessed, evaluation of TLI and SLI may help to better select patients with HER2+ and TNBC for neoadjuvant chemotherapy.
No takes yet. Share an insight, caveat, or question.
Li et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: